-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanubrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Opium (Opioid) Addiction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Opium (Opioid) Addiction Drug Details: Cannabidiol is under...
-
Product Insights
Likelihood of Approval Analysis for Opium Withdrawal Syndrome
Overview How likely is it that the drugs in Opium Withdrawal Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opium Withdrawal Syndrome Overview Opioid withdrawal syndrome is a life-threatening condition...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Chemotherapy Induced Peripheral Neuropathy Drug Details: Ibudilast (Ketas)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Amyotrophic Lateral Sclerosis Drug Details: Ibudilast (Ketas) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Alcohol Dependence Drug Details: Ibudilast (Ketas) is an anti-inflammatory and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Probenecid in Opium Withdrawal Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Probenecid in Opium Withdrawal Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Probenecid in Opium Withdrawal Syndrome Drug Details: Probenecid is under development...
-
Product Insights
Opium Withdrawal Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium Withdrawal Syndrome - Drugs In Development, 2023’, provides an overview of the Opium Withdrawal Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium Withdrawal Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...